Dr. Datsons Labs fate hangs in the decision of Official Liquidator’s action plan post winding up.

Dr. Datsons Labs fate hangs in the decision of Official Liquidator’s action plan post winding up. Anxious Retail Investors & Employees pin hope on Court Verdict of reopening of business & relisting by New Acquirer as troubled drug maker Dr. Datsons Labs Ltd faced deep in Financial Crisis,  lands Official Liquidator’s Court

Debashish Mishra*

Associate Editor – Pharmaleaders

debashish.mishra@network7mediagroup.com

Dr. Datsons Lab Ltd, formerly known as Aanjaneya Lifecare Ltd, specializing in manufacturing of bulk drugs & Contract manufacturing of key drugs & formulations is facing the new phase of its life as the old order of Management & control ended with the company informing the Exchange that the creditors of the Company was gearing towards winding up petitions, vide its order dated February 18, 2015 (uploaded on website on March 27, 2015), had also appointed the official liquidator to attach to the Bombay High Court as the provisional liquidator of Dr. Datsons Labs Limited (the Company ) and directed the provisional liquidator to forthwith take charge/possession of the Company s assets, properties, stock in trade, books of account, bank account and all other assets of the Company. Pursuant to the aforesaid order, on April 30, 2015, the Official Liquidator took possession of the registered office of the Company along with moveable’s lying therein. It may also be recalled that the trading of the shares came to an end till further notice & announcement of the Official Liquidator who is in-charge of taking all decisions.

The Background

Unable to pay the debts as well as pressure to raise working capitals to execute recent orders, Dr. Datsons Labs Management landed in big trouble. The High Court had ordered that Dr. Datsons Labs Ltd deserves to be wound up and Official Liquidator to take charge. However, small depositors are still finding it difficult to get their hard-earned money as the process is sub-judice & Company is not able to make any announcement as it will be termed as contempt of court . Many companies in the past , such as Micro Technologies, Yash Birla group – Zenith Birla (India) Ltd and Birla Power Solutions, Plethico Pharma and Ind Swift had faced the similar situations as they defaulted & delayed the payment of interest and principal on their fixed deposits (FDs). Pharmaleaders has written about these companies extensively in the past. Network 7 Media Group after receiving several complaints from depositors of Dr. Datsons Labs and decided to Investigate the Company & was given to understand  that it  sought capital from various sources, defaulted on almost all payments to not only to banks, but big lenders as well. Finally, it was ordered that Bombay High Court to be appointed as the Official Liquidator to take charge of the assets, properties and records of Micro Technologies and repay the lenders.

The Crucial Factors

The Management prior to the court order had initiated several actions to restructure & restrategize  the business operations & had appointed professionals to run the company & most importantly, the company had bagged some of the big orders both domestic as well as exports such as Eubage, Ochoa Labs, Almugdha Pharma etc. The understanding with these companies was that of executing the orders with the specified requirements. Pharmaleaders learnt from its top sources that the Company’s senior professionals requested the financial organizations & hectic negotiations was on with banks to lend money so that Dr. Datsons can start working with the orders as it had the expertise & manpower & technology but the negotiations did not materlize to arrange for the working capitals. Without working capital, it is impossible to execute these orders as the parties though placed the orders did not offer any advance amount.

Present Status

Now it appears that till the new investors take charge from the official liquidators, these orders will be of no value, however there are reasons to believe that given such a lucrative proposals & two state-of-the-art facility in Pune & Mahad, it is expected that the company may see a lease of life & the shares may again start trading after the regulators are satisfied with the explanations for relisting. Pharmaleaders tried to reach the Management for any news post the court verdict, it could not get a reply except an announcement via email from the Corporate Communications Department.“Further to your Query, the management of Dr Datsons Labs Ltd have been instructed by Hon. Curt to assist the Official Liquidators office to prepare the detailed report on functioning of the company and present it to the Hon Court. Currently the management cannot give out concrete plans as matter is sub-judice and we need instructions from Official Liquidators office on way forward. All Shareholders will receive communication from Official Liquidators office as they will be sending detailed communication to stock exchanges soon” – Corporate Communications Department

BSE_SUSPENTION LETTER_18-05-2015 copy NSE_SUSPENSION LETTER_18-05-2015 copy

Lets have a look at the role of the Official Liquidator as mentioned in the company law.

Main Functions of Official Liquidator:

  • Realization
  • Settlement
  • Distribution
  • Dissolution
  • Public Interest Reports under Section 394A

Report on private conducting of winding up proceedings by voluntarily liquidator   under Sections  497 and 509  

The Official Liquidator is appointed by the Central Government under section 448 of the Companies Act, 1956 attached to High Court of the State for the purpose of conducting liquidation proceedings of those companies which are ordered to be wound up by the High Court. Functionally the Official Liquidator is under the supervision and control of the High Court but administratively is under the control of the Central Government through the Regional Director.The Primary function of the Official liquidator is to administrate the assets of companies under liquidation, sale of the assets and realization of all debts of companies in liquidation for the purpose of distributing the same among the various creditors and other shareholders of the companies and to finally dissolve such companies after the affairs are completely concluded. When a company is put to winding up by an order of the High Court, the Official Liquidator attached to the said High Court takes possession of the company’s assets, books of accounts, etc. and liquidates the company as per the further orders of the High Court. The procedure of liquidation is prescribed under the Companies (Court) Rules, 1959. These rules are approved by the Honorable Supreme Court of India and notified by the Central Government. The duties and powers of the Official Liquidator as laid down in section 457 of the Companies Act, 1956 are mainly of, filing of claims against, the debtors for realization of the debts due to the company, sale of movable and immovable assets of the company taken possession by the Official Liquidator, institute criminal complaints and misfeasance proceedings against the former Directors of the company for their acts and omissions, breach of trust etc., invitation of claims from the creditors, adjudication of claims and settlement of list of creditors, payment to creditors by way of dividend and settlement of list of contributories wherever necessary, and payment of return of capital where the company’s assets exceeded its liability and finally dissolve the company under section 481 of the Companies Act,1956.

  1. POWERS AND DUTIES OF OFFICERS AND EMPLOYEES.

The Officers and employees are performing the duties as prescribed in the Companies Act, 1956 and the Companies (Court) Rules, 1959 subject to the supervision, control and orders of the High Court of Delhi. The duties are assigned to the officers and employees by the Official Liquidator to take possession of the assets and liabilities of the properties of the companies in liquidation. Arrange for sale of the properties and other duties as mentioned in Para 1 above. The Official Liquidator passes appropriate orders regarding the duties of officers and employees working under him.

  1. OFFICIAL LIQUIDATOR

In exercise of the powers conferred by Section 552 and clause (b) of the proviso to section 647, read with subsection (1) of section 642 of the Companies Act, 1956, the Central Government has framed the Companies (Official Liquidator’s Accounts) Rules, 1965.The Official Liquidators are officers appointed by the Central Government under Section 448 of the Companies act and are attached to the various High Courts. The Official Liquidators are under the administrative charge of the respective Regional Directors who supervise their functioning. In the conduct of the winding up of the companies, however, Official Liquidators act under the directions of the High Courts. The Primary function of the Official liquidator is to administer the assets of companies under liquidation, sale of the assets and realization of all debts of companies in liquidation for the purpose of distributing the same among the various creditors and other shareholders of the companies and to finally dissolve such companies after the affairs are completely concluded. When a company is put to winding up by an order of the High Court, the Official Liquidator attached to the said High Court takes possession of the company’s assets, books of accounts, etc. and liquidates the company as per the further orders of the High Court. The procedure of liquidation is prescribed under the Companies (Court) Rules, 1959. These rules are approved by the Honourable Supreme Court of India and notified by the Central Government.

  1. WHO CAN BE APPOINTED AS OFFICIAL LIQUIDATOR?

A member from the panel of the professional firms of chartered accountants, advocates, company secretaries, cost and work accountants which the central government may constitute. Body corporate approved by central government. Whole-time or part-time officer appointed by the central government.

  1. ROLE OF OFFICIAL LIQUIDATOR

The role of official liquidator has been well discussed in various provisions in the Companies Act 1956 and the Companies (Official Liquidator’s Accounts) Rules, 1965. Sections 448 to 463 of the Companies Act 1956 deals with the overall role of official liquidators in winding up proceedings. Let’s have a sneak view of the provisions relating to liquidators:

SECTION: MATTERS DEALING UNDER THE SAID SECTIONS

  • 448 APPOINTMENT OF OFFICIAL LIQUIDATOR
  • 449 OFFICIAL LIQUIDATOR TO BE LIQUIDATOR
  • 450 APPOINTMENT AND POWERS OF PROVISIONAL LIQUIDATOR
  • 451 GENERAL PROVISIONS AS TO LIQUIDATORS
  • 452 STYLE ETC OF LIQUIDATOR
  • 453 RECEIVER NOT TO BE APPOINTED OF ASSETS WITH LIQUIDATOR
  • 454 STATEMENT OF AFFAIRS TO BE MADE TO OFFICIAL LIQUIDATOR
  • 455 REPORT BY OFFICIAL LIQUIDATOR
  • 456 CUSTODY OF COMPANY’S PROPERTY
  • 457 POWERS OF LIQUIDATOR
  • 458 DISCRETION OF LIQUIDATOR
  • 458A EXCLUSION OF CERTAIN TIME IN COMPUTING PERIODS OF LIMITATION
  • 459 PROVISION FOR LEGAL ASSISTANCE TO LIQUIDATOR
  • 460 EXERCISE AND CONTROL OF LIQUIDATOR’S POWERS
  • 461 BOOKS TO BE KEPT BY LIQUIDATOR
  • 462 AUDIT OF LIQUIDATOR’S ACCOUNTS
  • 463 CONTROL OF CENTRAL GOVERNMENT OVER LIQUIDATORS.

…………………………………………………………………………………………………..

  • As per the Companies (Official Liquidator’s Accounts) Rules, 1965, the liquidator has to comply with the following:
  • The Official Liquidator shall maintain in his office separate account in respect of each company under his charge.
  • The Official Liquidator shall also maintain a Central Cash Book to record all cash transactions; such other books as may be necessary to work out the periodical reconciliation of the balances in the official liquidators’ account.
  • Every Official Liquidator shall, with the approval of the Central Government, open a personal ledger account at the nearest branch or agency of the Reserve Bank to be called the “Official Liquidator’s Account” which shall be a combined account in respect of all the companies under his charge.
  • Payments made in cash and those made by cheque shall be remitted to the Reserve Bank under separate challans.
  • The acknowledgment of the Reserve Bank shall be obtained for all moneys remitted into the Reserve Bank to the credit of the said account.
  • The Official Liquidator shall, at the end of every three months, examine the account of each company in his charge to ascertain what moneys are available for investment and record in the record book of the company the fact of his having examined the accounts, the decision taken by him regarding the investment, and in case he decides not to invest any surplus fund, the reasons for such decisions.

POWERS OF LIQUIDATOR IN WINDING UP:

  • In compulsory winding up of a company:
  • As per section 457(1) of The Companies Act 1956, the liquidator has the following powers with the sanction of court:
  • to institute and defend any suit, prosecution or other legal proceeding, civil or criminal, in the name and on behalf of the company;
  • to carry on the business of the company;
  • to sell the immovable and movable property and actionable claims of the company by public auction or private contract;
  • to raise on the security of assets of the company any money requisite;
  • to do all such acts necessary for winding up the affairs of the company and distributing its assets.
  • As per section 457(2) of The Companies act 1956, the liquidator has the following powers without obtaining the sanction of court:
  • to do all acts and to execute all deeds, receipts and documents in the name and on behalf of company and to use common seal of the company for that purpose;
  • to inspect the records and returns of company;
  • to prove, rank and claim in the insolvency of any company;
  • to draw, accept, make and endorse any negotiable instruments in the name and on behalf of the company;
  • to appoint an agent to do any business which the liquidator is unable to do himself.
  1. In winding up subject to the supervision of court.
  • As per section 546 of The Companies Act 1956, the liquidator has the following powers with the sanction of court:
  • to pay any classes of creditors in full;
  • to make any compromise or arrangement with the creditors to have any claim ascertained;
  • to compromise any call, debt or liability.
  1. In voluntary winding up of company

Voluntary liquidator may exercise the following powers with the sanction of special resolution in the case of members’ voluntary winding up; with the sanction of court or committee of inspection in the case of creditors’ voluntary winding up; with the sanction of creditors if there is no such committee:

  • to institute and defend any suit, prosecution or other legal proceeding, civil or criminal, in the name and on behalf of the company;
  • to carry on the business of the company;
  • to sell the immovable and movable property and actionable claims of the company by public auction or private contract;
  • to raise on the security of assets of the company any money requisite.
  1. The following powers can be exercised by him without any sanction:
  • to do all acts and to execute all deeds ,receipts and documents in the name and on behalf of company and to use common seal of the company for that purpose;
  • to inspect the records and returns of company;
  • to prove, rank and claim in the insolvency of any company;
  • to draw, accept, make and endorse any negotiable instruments in the name and on behalf of the company;
  • to appoint an agent to do any business which the liquidator is unable to do himself;
  • to exercise the power of court of settling the list of contributories;
  • to exercise the power of court of making calls;
  • to pay debts of company and adjust the rights of contributories among themselves.

DUTIES OF THE OFFICIAL LIQUIDATOR

  1. Investigation

Where a winding-up order is made by the court the official receiver has a statutory duty to investigate–

  1. a) If the company has failed, the causes of the failure; and
  2. b) Generally, the promotion, formation, business, dealings and affairs of the company. This applies to all cases including those where an insolvency practitioner is appointed liquidator by the court immediately on the making of the winding-up order.

The official receiver may make a report to the court if he/she thinks fit, though this is carried out rarely.

  1. Official receiver as liquidator

The official receiver becomes liquidator immediately the winding-up order is made and will remain so until someone else becomes liquidator. He/she also becomes liquidator during any subsequent vacancy. The official receiver has a duty to protect the company’s assets and, where appropriate, to take into custody or under his/her control all property, etc. to which the company is or appears to be entitled, to realise and distribute the same to the company’s creditors and, if there is a surplus, to the persons entitled to it.

  1. Realisation of assets at the initial stage

There is no reason why the official receiver should not use his/her powers as liquidator to commence the realisation of assets, where the assets involved are easy to realise and, particularly, where an asset may be rendered valueless by the date of the first meeting, such as bulky items of stock which are expensive to store or small value bank balances held in accounts that incur charges. Even if the early realisation of an asset were to prejudice the appointment of an insolvency practitioner, the official receiver should act in the best interests of creditors and seek realisation.

  1. Statement of affairs

The official liquidator must decide whether to require a statement of affairs. It is not usually the case that a statement of affairs will be required before the first interview with the director(s) and generally the information supplied in form PIQC relating to assets and liabilities will be used rather than a separate statement of affairs being required.If the company has been subject to earlier insolvency proceedings a statement of affairs may have been prepared in relation to those proceedings.Reference should also be made to the chapter pertaining to– Statements of affairs.

  1. Case files

The official liquidator is required to maintain a case file in respect of each winding up. The file is divided into ten parts and papers are filed within those parts as follows:

  • Preliminary examination papers
  • Further investigation
  • Court papers
  • Statutory notices
  • Correspondence
  • Meetings, reports to creditors, notices and proofs
  • Assets
  • Closing/IP handover
  • Miscellaneous
  1. Confidentiality

The official liquidator must not disclose information about a case to any person who does not have a legitimate reason to have the details of the case.

  1. Insolvency Practitioner appointed liquidator immediately

Where a winding – up order is made immediately upon the appointment of an administrator ceasing to have effect, or where there is a supervisor of a voluntary arrangement in office, the court may appoint the former administrator or supervisor as liquidator of the company.In such circumstances, the official liquidator remains under a statutory duty to investigate, to give notice of, advertise and gazette the order and to provide information to creditors and contributories. Any inspection of the company’s books and papers will need to be made with the arrangement of the liquidator – possibly, by inspecting the records at their offices.  The liquidator has a duty to co-operate with the official receiver’s investigations, including making company records available.The official liquidator does not have to summon meetings of creditors and contributories or issue notice of no meeting. Where a liquidator is appointed by the court in the circumstances mentioned, it is the liquidator’s duty to send forms of proof of debt. A proof of debt must be sent to any creditor of the company on request.The official liquidator may encounter the involvement of insolvency practitioners in respect of other insolvency proceedings involving the company.

…………………………………………………………………………………………………………………………..

The Visionary Entrepreneur of Elder Pharma late Jagdish Saxena was a man of emotions & a compassionate leader. Remembering the leader!

The Visionary Entrepreneur of Elder Pharma late Jagdish Saxena was a man of emotions &  a compassionate leader.

 

If there’s one trait that embodies late visionary chairman of Elder Pharma Jagdish Saxena, it’s perhaps the man’s mettle. The first public hint of that came in 1987 when Saxena was at the top of his career. In 27 years he had gone from a commissioned officer in the Indian Air Force to managing director of Dehli-based pharmaceutical Waltner Bushnell. That’s when his management dropped a bomb on him. They wanted to shutter some plants and unload 300 employees. He would have none of it. He took the 300 people who were about to lose their jobs and started Elder Pharma.

The accidental entrepreneur whose style of leadership in driving business is still deep in my thought process, as a human being, he was loved by all, by his employees & those who came to meet him for business. I have reasons to believe that truly an era of human touch leadership ended though both Anuj & Alok are very lovable & capable. Jagdish Saxena was a man whom you could count in difficult times.

 

Satya Brahma

Editor-In-Chief

Network 7 Media Group

Early Motherhood in Odisha cause of concern, 11,000 girls in Odisha are mothers before 15

The 2011 Census has come up with the shocking disclosure that girls below the age of 15 in Odisha have given birth to babies when they should have been going to school. The exact figure, the data shows, of girls attaining motherhood even before 15 is 11,000. The figures point a finger to the failure of social welfare programmes and campaigns to contain early marriages and pregnancies. Of the 59.09 lakh girls below the age of 15, 41,729 girls (0.7%) were already married. Around one-fourth of the married girls (10,685) in the same age group had delivered before celebrating their 15th birthday. While 3,896 (9.34% of those married) had become mothers of at least one child, 6,789 girls (16.27%) had delivered two children. Women and child development minister Usha Devi said, “We need to focus more on creating awareness among parents because that is the only way to prevent underage marriages and pregnancies.”

Women’s rights campaigners attribute the early pregnancies to three factors. “Tribals have a tendency to marry off their boys and girls early. Second, economically weak sections don’t wait for 18 years for their girl’s marriage for purposes of social security,” said Namrata Chadha, a women’s rights campaigner. RD Women’s College principal Chitrangada Samanta Singhar said the findings are shocking. “The Right to Education Act envisages education for all children below 14. But it seems many girls in this age group are burdened with children,” she said. “Early pregnancy is dangerous for both the mother and child. This could be a reason behind the high infant and maternal mortality rates in the state,” said gynaecologist R K Purohit. Odisha’s maternal mortality ratio (MMR) per 1,000 women is 235 compared to the all-India figure of 178. The infant mortality rate is 57 compared to 44 at the national level (SRS-2012). In neighbouring Chhattisgarh, around 6,400 girls become mothers before 15, while in Jharkhand their number stands at over 12,000. At the national level, 18.12 lakh of the 17.80 crore girls below 15 years are married. Around 4.5 lakh in the age group (around 25% of those married) had delivered; while 1.36 lakh had delivered one child, 3.20 lakh had delivered two.

In the age group of 15-19 years, there are 2.90 lakh married women in Odisha. Of them, over 65,000 (22.52%) had given birth to one child, over 12,000 (4.23%) to two children, 4,400 (1.55%) to three children and 5,500 (1.92%) to four children. Out of the total 2 crore women in Odisha reported during the census count, 1.19 crore are married (57.76%) and gave birth to on an average 2.6 children. Of the total 1.19 crore married women, 14.27% have not given birth to any child. While 17.04% delivered one child, 22.93% gave birth to two, 17.74% to three, 12.23% to four, 7.13% to five, 4.10% to six and 4.56% to seven or more.

London based Healthcare Giant set to be the new promoters of Dr. Datsons Labs Ltd

London based Healthcare Giant set to be the new promoters of Dr. Datsons Labs Ltd. Dr. Datsons Labs aggressive marketing & new orders worth over 400 crores will sail through with the new Cash Rich Promoters

Debashish Mishra

 

It is widely known that Dr. Datsons Labs Ltd is in the process of one time settlement with the Bank which is to the tune of only 80 crores & clearly the assests of the company can easily be valued at about 175 Crores . With the new London based promoter coming on Board to take control of the company for a complete overhaul where the management of the company is already in place with a professionally managed top management & the work force of 250 employees. The present structure of the company is run by institutions spearheaded by  Dr. Rajendra Kamat as the Vice-Chairman & MD, Mr Saleem Talim as the CEO, & Mr. Shashikant B. Shinde as Executive Director. Mr. Mahesh Vaidya has been appointed as Non Executive Chairman of the Company with effect from February 15, 2015 as per the company’s announcement to the BSE. The top level sources to the London based healthcare Firm’s leadership reveal that a deal has indeed been stuck with Dr. Datsons Labs Ltd for an undisclosed amount, but a definite picture of recovery back to business. The deal involves the taking over of the company as new promoter Group. The London based Company besides having operations worldwide is also setting up a huge $200m multi-specialty hospital in Mumbai for cancer and trauma surgery, due to be commissioned in August 2015. The Group clearly wants to use Dr. Datsons Labs Ltd by making it as a hub to supply quality medicines to the world market. The old clients of Dr. Datsons Labs will also make a comeback to do business with a reasonable price offering high quality standards..

Sources close to Pharmaleaders reveal that a big time London based group having worldwide operations with a total value of more than 5 Billions $ with interest in Healthcare, finance, banking operations is indeed set to take over Dr. Datsons Labs. The talks between the two companies are almost complete where the London based company has constituted a project management group consisting of consultants of repute in healthcare as well as financial background well versed with the present market conditions. It is believed that the new promoters will streamline the operations with manufacturing, production, R&D, NDDS, NCE’s & additional capabilities to foray into cancer research. The present  valuation of the company is definitely much bigger & the regular business will be hassle free once the new promoter group list the stocks outside india. The  Regulatory & statutory Bodies in Singapore or in London stock exchanges are definitely  far better than India & the company can post a turnover of  500 Crores. The New formation will retain the top management executives.

It may be recalled that with the new management in Board, the company has bagged some of the most enviable orders from both overseas & domestic companies to exports in anti-malarial & anti-cancer drugs. Some of the top orders include Eubage Laboratory, the Belgium-based manufacturer of nutrients and nutritional supplements,  to invest $ 17 million (about Rs 104 crore) 20 nutraceutical products to be manufactured at their Pune formulations facilities, an estimated 80 crore order from Yemen’s Al-Mugdh Pharma for anti-malarial drugs, partnership with Clinton Foundation to supply Anti-Malarial Drugs to Eliminate Malaria on UNITAID-CHAI Malaria Treatment Project 2015. Lately Dr. Datsons Labs also received order from a Delhi based exports company through an Exclusive Contract Manufacturing Partnership for Cancer Drugs worth 120 Crore with Dr. Datsons Labs Ltd to be exported to Europe. In addition to this Dr. Datsons Labs Ltd has already on board some top domestic players such as Glenmark, Universal Healthcare, Pharmed Europe, Ltd. and Zenufa Labs among others. To the advantage of the Acquirer are some top facilities. Dr Datson’s core strength lies in the research and manufacture of quality lozenges, controlled substances in formulations, anti-malarials and niche APIs. And CRAMS . The Company’s culture of manufacturing excellence is centered on quality control, quality assurance, in-process control guidelines and training. Corporate Performance Review of the Company The Company’s manufacturing locations are integrated and linked by high-speed networks to deliver products to markets at the right time and price. The Company’s facilities are UK-MHRA and EU-GMP-compliant, and ISO 9001:2008, ISO 14001:2004 and ISO 22000- certified; these enhance the confidence of global Pharma players. The Company designed the quinine extraction equipment in-house while maintaining stringent quality parameters, emerging as one of the most cost-effective quinine manufacturers. The Quinine Sulphate and other salts received approvals from US, EU and Canadian customers.

Dr Datsons Labs

The reason for the company to sell the business to the London based group is quite clear that the company has been facing liquidity issues for Its working Capital Requirement, hence performance of manufacturing operations are greatly affected , to overcome the same Dr. Datsons Labs had undertaken steps to raise equity through sale of stake , bringing in strategic investors and even selling the assets so that the company gets in required funding for its Working Capital & Capex Program. Dr. Datsons was looking for long term investors who can take forward the legacy of the company.

 

Ochoa Labs to Expand base in Europe through an Exclusive Contract Manufacturing Partnership for Cancer Drugs worth 120 Crore with Dr. Datsons Labs Ltd

Ochoa Labs to Expand base in Europe through an Exclusive Contract Manufacturing Partnership for Cancer Drugs worth 120 Crore with Dr. Datsons Labs Ltd

 

Dr. Datsond Labs Ltd will manufacture on an exclusive basis to the Ochoa Labs Requirements of DOCETAXEL ANHYDROUS,IRINOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE,SEMI SYNTHETIC PACLITAXEL, GEMCITABINE HYDROCHLORIDE, CAPECITABINE, IMATINIB MESYLATE GEFITINIB in finished formulations

Thursday, March 21, 2015, Mumbai, Maharashtra, India : . Dr. Datsons Labs Ltd, HSL Code: AANLIF, BSE Code: 533412, NSE Symbol: DRDATSONS,ISIN INE928K01013 has forged a potential collaboration with Delhi based Pharma Company Ochoa Laboratories Ltd to produce oncology drugs to cater to the European market worth 120 Crore. Dr. Datsons Labs has received the letter on 11th March 2015 for undertaking the contract manufacturing of the cancer drugs on a stipulated time line.

Speaking on the development, Dr. Rajendra Kamat, Vice-Chairman & MD of Dr Datsons Labs Ltd said “ We are excited about the latest order confirmation from Ochoa Labs which was there in the proposal since a year & all our clinical data & dossiers are accepted &  we are  committed to manufacturing excellence in Cancer products at par excellence . As a premier oncology manufacturer from India, we are particular about maintaining the quality of our medicines so that they match international standards. We manufacture cancer treatment medicines at affordable prices so that it is available universally to all affected patients. As a manufacturer of medicines dedicated to treating cancer, we cover the entire gamut of medication including tablets, capsules, injections and ointments. These drugs are used in chemotherapy, immunotherapy, surgery or hormone therapy. Like other formulations, our cancer drugs are prepared under strict hygienic conditions. Manufacture of oncologic formulations are done keeping in mind the exact form of therapy needed. The formulations and their strengths vary accordingly. Each drug is carefully examined and tested keeping in compliance with leading drug manufacturing standards. We procure ingredients from authentic sources so as to maintain highest quality standards of our products. Several tests are conducted so as to ensure genuineness of our drugs and formulations. We maintain national as well as international standards of quality of EU-GMP or UK-MHRA, WHO-GMP and many others.

“The real challenge will be to run the second plant with full capacity which will necessitate additional  manpower & resources. Though the plant is fully equipped, our biggest challenge will be to meet the quality parameters of the guidelines. We are hopeful for a long lasting relationship with Ochoa Labs which will be a continued & steady source of revenue & our top line growth will increase in the last quarter of the fiscal” said Dr. Rajendra Kamat in the release.

Sunil Chopra, Director, Ochoa Laboratories Ltd, said, “We believe that the coming together of Dr. Datsons’s innovative oncology range with Ochoa’s strong persecute in Europe  empowers us to provide an even wider array of value driven healthcare solutions & We are extremely optimistic about its prospects and committed to creating a long-term partnership with Dr. Datsons Labs”. Realising that managing the complexities of cancer necessitates the availability of a wide range of products and supporting therapies, we found that combining our efforts and product range with that of Emcure Oncology, makes immense sense for both companies.”.

 

“We have received orders to export the anti cancer drugs to Europe & since we don’t have a specialized plant on this to exports products such as DOCETAXEL ANHYDROUS,IRINOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE,SEMI SYNTHETIC PACLITAXEL,, Dr. Datsons facilities are ideal for us to source the finished formulations under our brand name to sell in regions such as UK, Germany, France, Italy and Spain under one distribution point in London. We will laso have an advantage of getting the sourcing from Dr. Datsons Labs at a reasonable rate compared to other Contract Manufacturing Companies producing Anti-Cancer Drugs.” We will start commercializing the products in Europe in the third quarter of 2015 & our commitment to the export market is to make the product available in Nov Dec 2015”.

cancer-drug-on-banner copy

It may be recalled that a new study point out the growing requirements of cancer drugs in the European region & more than 500,000 patients across the five largest European countries such as UK, Germany, France, Italy and Spain have been treated with a new form of personalised cancer drug, according to new research. It found that between 500,000 and 600,000 patients are currently treated with targeted therapies in these countries, all of which have a total population of around 320m. In the five countries studied, Cegedim’s analysis found targeted therapies represent an average of 32% of all cancer drugs used – the remaining 68% being cheaper chemotherapy drugs and hormonal treatments, Breast cancer is the most commonly treated, accounting for around 16% of all tumours across all five countries. Non-small cell lung cancer (NSCLC) was a close second, although the rates of targeted drug use for the disease varied greatly among the individual countries.In France the use was 15% while it was 12.3% in Italy and Germany, but 11% in Spain and only 7.1% in the UK. In fact the UK had the lowest level of cancer patients using these new types of treatments, with 67.9%. Spain had the highest level at 71.9%, followed closely by Italy with 71.6%. Cegedim says that these differences are influenced by the launch dates of the drugs, as well as the health authority and market access policies in each country. Patients with pancreatic cancer, for which there are few personalised drugs licensed in Europe, made the least use of personalised medicines, with only around 2.5% of patients across the five countries receiving new treatments for the disease.

 

About Ochoa Laboratories Ltd

 

Ochoa Laboratories Ltd. operates as a pharmaceutical company in India. It offers pharmaceutical formulations and dosage forms, including vasoprotectors, dermatology products, antibiotics, and antioxidants and nutritional supplements. The company has operations in Europe, Tanzania, Zambia, Uganda, Venezuela, Costa Rica, and various Latin American countries. Ochoa Laboratories Pvt. Ltd. was incorporated in 1993 and is based in Noida, India with an additional office in New Delhi. In 2009 Ranbaxy Laboratories Ltd acquired trademarks, product dossiers and marketing rights from Ochoa Laboratories Ltd for its entire range of dermatological and lifestyle products for the domestic marketing.  Presently Ochoa Laboratories only is engaged in the export market & we have widened our marketing to Europe in a big way.

Dr. Datsons Labs to partner with Clinton Foundation to supply Anti-Malarial Drugs to Eliminate Malaria on UNITAID-CHAI Malaria Treatment Project 2015

Dr. Datsons Labs to partner with Clinton Foundation to supply Anti-Malarial Drugs to Eliminate Malaria on UNITAID-CHAI Malaria Treatment Project 2015

 The Clinton Health Access Initiative (CHAI)’s Commitment to create a malaria-free zone in Africa awards contract to Dr. Datsons Labs to supply Artemisinin-based combination therapies” (ACTs) on a discounted price.

 

Monday,9th March 2015, Mumbai, Maharashtra. Indian Drug maker Dr. Datsons Labs Ltd specializing in manufacturing of Anti-Malarial drugs has received the proposal to supply the Artemisinin-based combination therapies” (ACTs) to The Clinton Health Access Initiative (CHAI), the healthcare project of the Clinton Foundation. Dr. Datsons Labs Ltd will be making a a significant deal though there Is a a minimum pricing that the company will be working on. The volume will be huge because it will be supplied to most of the African countries. In the UNITAID-CHAI Malaria Treatment Project 2015, other big players such as Cipla, Ipca & other Indian players are already on the approved list of The Clinton Health Access Initiative (CHAI) to supply the drugs.

Speaking on the deal with The Clinton Health Access Initiative (CHAI)’s UNITAID-CHAI Malaria Treatment Project 2015, Dr. Rajendra Kamat, Vice-Chairman & MD, Dr. Datsons Labs Ltd said, This is a huge order & the clauses in the Agreement are time bound with several quality aspects to adhere & Dr. Datsons Labs Ltd is fully equipped to meet the challenges of the order. We are also presently working on the recent orders of Marketing And Supply Agreement with Yemen’s AL-MUGDH PHARMA to sell its drugs in YEMEN, We are quite confident that we will bounce back again as a leading player both in international & domestic market. We will be working on two shifts from April onwards to the new orders received from Eubage Laboratory’s 20 innovative food supplements formulations coming under the neutraceutical foray.

 

Malaria is a mosquito-borne disease caused by a parasite. People with malaria often experience fever, chills, and flu-like illness. Left untreated, they may develop severe complications and die. According to the World Health Organization, malaria caused an estimated 584,000 deaths worldwide in 2013. However, malaria is preventable and treatable. Increased investments and coordinated global health efforts have resulted in a 47 percent decrease in malaria mortality rates since 2000. With continued commitment and progress, a malaria-free generation will be within our reach.

Founded in 2002, by President William J. Clinton, the Clinton Health Access Initiative (CHAI) is a global health organization committed to strengthening integrated health systems around the world and expanding access to care and treatment for HIV/AIDS, Malaria and other illnesses. Based on the premise that business oriented strategy can facilitate solutions to global health challenges, CHAI acts as a catalyst to mobilize new resources and optimize the impact of these resources to save lives, via improved organization of commodity markets and more effective local management. CHAI helped the Government of South Africa to achieve a 53 percent price reduction for antiretroviral drugs; CHAI’s support will help the Government achieve US$960 million in savings over four years. In the past decade, remarkable advances have been made in treating and preventing malaria. Better medicines and long-lasting bed nets have been developed. Donor funding for malaria control has dramatically increased from $153 million in 2000 to over $1 billion in 2010. Indeed, the focus of many countries has recently shifted from malaria control to malaria elimination. Not surprisingly, this rapid infusion of new technology, increased funding, and policy reform has created a new set of challenges for the governments of malaria endemic countries. CHAI works in partnership with governments to address these challenges, creating evidence-based solutions tailor-made to each unique situation. In the past decade, remarkable advances have been made in treating and preventing malaria. Better medicines and long-lasting bed nets have been developed. Donor funding for malaria control has dramatically increased from $153 million in 2000 to over $1 billion in 2010. Indeed, the focus of many countries has recently shifted from malaria control to malaria elimination. Not surprisingly, this rapid infusion of new technology, increased funding, and policy reform has created a new set of challenges for the governments of malaria endemic countries. CHAI works in partnership with governments to address these challenges, creating evidence-based solutions tailor-made to each unique situation. CHAI’s work on malaria treatment began in Tanzania, which was, like most of Africa, flooded with cheap, ineffective malaria drugs called monotherapies. While government programs were making the switch to effective artemisinin-based combination therapies (ACTs), this treatment remained prohibitively expensive at the pharmacies where most Africans buy their drugs.

CHAI is currently working with AMFm countries to expand access to malaria treatment by increasing the market penetration of ACTs to over 50 percent in the next year. This initiative includes helping new ACTs gain market entry and uptake by providing technical assistance, regulatory expertise, and cost-optimization support to the companies that manufacture them. CHAI is also continuing our work to improve the sustainability and efficiency of malaria financing, including the exploration of novel mechanisms like cash-on-delivery, which pays for progress made toward targets. Additionally, CHAI is helping Swaziland advance toward becoming the first mainland African country to eliminate malaria by ramping up effective surveillance to track down and diagnose every case. Even a few years ago, people thought that eliminating malaria in a sub-Saharan African country was impossible and yet Swaziland is now on the verge of achieving that remarkable feat.

About Dr.Datsons Labs Ltd

Dr.Datsons Labs Ltd., formerly Aanjaneya Lifecare Limited, is an India-based integrated pharmaceutical company. The Company is engaged in the manufacturing and marketing capabilities in Contract Research and Manufacturing Services, and active pharmaceutical ingredients. The Company focuses on anti-malarial and finished dosage forms (FDFs), catering to diverse therapeutic segments. The Company manufactures second generation anti-malarial APIs like quinine and salts as well as third generation anti-malarial products like Artemisinin-based salts. The Company engages in contract manufacturing for leading Indian pharmaceutical brands namely Wockhardt, Cipla, Zydus Cadila, Lupin and Glenmark, among others.  The Company’s subsidiaries include Eros Pharmachem Pte Limited, Aanj Pharmalabs Limited Fze, Fair Success (Hongkong) Limited and Dr. Datsons Labs Limited (the United Kingdom.

………………………………………………………………………………………………………

Contact

Mr. Yogesh Patel

Company Secretary

Dr. Datsons Labs.Ltd

Dr.Datsons House, Plot No W-91D Taloja MIDC 410208,

Raigad Dist, Maharashtra State, India

cs@drdatsons.com

Ph: (+91) 22-27402223 / 24

Fax: (+91) 22-27411837

Biocon Chief Kiran Mazumdar Shaw on Union Budget 2015

The Finance minister’s budget speech was very compelling. He gave me an impression that he has broadly met everyone’s expectations. The fine print of the budget needs to be carefully analysed to understand the impact that this budget would have. Now, it is about delivering what is required to achieve the key points of the 2015 budget proposal, which doubles up as a very good vision document on the direction of the Indian Economy. I think the Finance Minister has touched upon a lot of key areas, but now it is about delivering on the positive proposals put forth in this budget.

In terms of addressing key constituencies, the Finance Minister did a good job of addressing both the social sector and the corporate sector. This budget has certainly raised important questions in the realm of resource management. How do you raise resources and how do you free up resources? The measures taken to monetize gold is a key step forward. Moreover, the budget has made a strong attempt to put money back in the hands of the people. Raising Health Insurance Premiums exemption limit, increasing National Pension Scheme contribution exemption limit along with increasing Transport Allowance exemption effectively means that an individual tax payer can save up to Rs. 4,44,200.

The easing of corporate tax is definitely going to bring cheer to corporates, as it will relieve them of a high tax burden and they can direct their resources to making Investments that help India grow. In terms of other taxation reforms, the government has made a positive move by ensuring that the Wealth Taxes are abolished and 2% surcharge is added to tax individuals whose taxable income is above 1 crore. Apparently, this measure will bring in an additional Rs. 9,000 crores into the government coffers and hence, it is a positive proposal.

Addressing the “Make In India” Mantra

The Finance Minister rightly touched upon the fact that the Skill India and Digital India initiatives are drivers for “Make In India”. The thrust laid on indigenous defence production as well as the focus on renewable energy will certainly push the agenda for “Make In India” forward.

Infrastructure Push

There has been a corpus of Rs. 70,000 crores allocated to Infrastructure, which will definitely lead to the development of major infrastructure projects. Along with the proposal to set up major power plants, the infrastructure push in this budget is set to surge India ahead. The proposal to revitalise the PPP model for infrastructure development and the subsequent bearing of majority risk by the govt. will definitely yield positive results for infrastructure. Additionally, the tax – free bonds in rail roads and irrigation projects will spur investments in critical infrastructure.

Laying the Groundwork to Enable ‘A Startup Culture’

I was impressed by the Finance Minister’s announcement of the Atal Innovation Mission to be established which will draw on expertise of entrepreneurs, and researchers to foster scientific innovations. An allocation of Rs. 150 crores has been made for this purpose. Moreover, it is heartening to see the Finance Minister to allocate Rs. 1000 crores for start-ups. Although, the fine print will give more clarity on this allocation, but nevertheless it is a boost. The talk of creating world class incubators is welcome, as long as they facilitate the creation of incubators by people who know the business.

Access to Health

Healthcare is probably one of the sectors, which hasn’t been given the due importance in this budget. The Finance Minister could have proved its commitment to the universal health coverage and increased public health spending. This was one of the areas, where the budget could have done much more and clearly it failed in this regard.

Having said that, the setting up of AIIMS in Jammu and Kashmir, Punjab, Tamil Nadu, Himachal Pradesh, Bihar and Assam pushes forth Healthcare education and research in these states.

Conclusion

The Finance Minister has certainly laid a very positive roadmap for the future. One can only hope that the govt. delivers on its budget proposals in an effective manner and reaches the destination that it has shown. Clearly, India is Poised and the Flight Path is cleared for takeoff!

Kiran Mazumdar Shaw*

Indian Pharma Industry Needs a Big Investment Reforms & Push from Transformational Union Budget 2015-16 ” – Dr. Rajendra Kamat , VC & MD, Dr. Datsons Labs Ltd.

Indian Pharma Industry Needs a Big Investment Reforms & Push from Transformational Union Budget 2015-16 ” – Dr. Rajendra Kamat , VC & MD, Dr. Datsons Labs Ltd.

Dr. Rajendra Kamat , VC & MD, Dr. Datsons Labs Ltd. expressed hope that the Finance Minister Arun Jaitley will  accord enhanced tax incentives for research and development (R&D) activities in the pharmaceutical sector in the forthcoming Budget to be announced on February 28. In its Budget proposals, the Commerce Ministry has sought “weighted average tax benefit of 400 per cent for R&D activities for the sector”.

Midsized companies like us will look at more positive agenda & push from the forthcoming budget & clarity of direction on tax reforms & FDI.

“There is an urgent need to boost R&D in the pharma sector. India is the hub of generic medicines. It contributes significantly to the country’s total exports,” Dr. Kamat expressed that the industry will get fresh incentives as annually, India exports pharmaceutical products worth $10 billion. The market size of the industry is around Rs. 1 lakh crore.The need for special financial package for the pharma sector has been highlighted in various fora.The pharma sector is a capital intensive sector. Besides R&D expenditure, regulatory requirements require large funds. All quality investments should be treated on par with R&D to provide incentives to the industry,” the official added.

Dr. Datsons Lab Ltd, formerly known as Aanjaneya Lifecare Ltd, BSE code (533412) is a vertically integrated company having state-of-the-art; WHO GMP approved facilities for manufacturing bulk drugs at Mahad and finished dosage forms at Pirungut near Pune. It is one of the largest contract manufacturers of codeine based cough syrups in India. The company exclusively manufactures the Codorex Brand of Zydus Cadilla and Codilite Brand of Tablets India Ltd. amongst others.The company raised about Rs. 117 crore from its IPO and the funds are being used to built new capacities along with the refurbishing of Research & Development centre. The new facilities being created as part of CAPEX are using eco friendly, recyclable material and will be rated by LEEDS once completed.The Facilities being established will comply with the latest European & US guidelines. With new capacities to be added in next 6 to 9 months the company will be expanding operations in emerging markets of South East Asia, Africa & South & Central America and its domestic operation in branded generics segment. The company with its manufacturing facilities –in Mahad, Hyderabad and Pune has to its credit many achievements. It is the world’s third-largest manufacturer of quinine salts in the world . Only nine companies globally manufacture quinine salts.One of the largest codeine based formlulations manufacturer in the pharmaceutical sector. One of the largest manufacturer of multi- flavored Lozenges in  medical products in India. The company pioneered the recognition that lozenges represent a stable platform for the delivery of pharmaceutical and nutraceutical ingredients. Dr. Datson’s Nicco Nil lozenge is a first-of-its-kind  hard boiled lozenge remedy for smoking de-addition; its Relacs is a first-time lozenge against insomnia and Arecta Plus, a lozenge variant for Erectile Dysfunction, is a first of its kind . The company has an expertise in opportunity spotting and innovation. The company’s success has been built on a business model that integrates Research, Innovation and Knowledge. The company has invested in building proprietary Knowledge through research and acquisitions. Dr. Datson’s competence has been validated through patents granted by international and Indian authorities. Production of Quinine Sulphate increased 30% in 2011-2012. Sales of Quinine Sulphate grew 45%. Exports increased 250% from Rs 10 Crore to Rs 31 crore. Added 35 international and 50 domestic clients. Completed trials for Bromexine(expectorant)a new API that will be launched in 2012-1023. Highlights 2011-2012 for Finished Dosage Forms. Launched ‘Rancorex’ an in-house codine based cough syrup brand for the first time in its history. received the Kenya PPB GMP approval from all facilities namely lozenges,liquids and ointments. Received registration for ‘Arecta Plus’(a lozenge variant of Viagra tablets)from Sierrs Leone and Libya; received the first export order for this product to be executed in 2012-2013.

New Leadership take charge at Dr. Datsons Labs Ltd, New Management to drive export market of Dr. Datsons’s branded generics.

New Leadership take charge at Dr. Datsons Labs Ltd, New Management to drive export market of Dr. Datsons’s branded generics.

 Mr. Mahesh Vaidya takes charge as the Vice Chairman and Managing Director & Mr. Sameer Talim as the  new Chief Executive officer.

 Dr Datsons News image ceo interview

Saturday, 14th February 2015, Mumbai, Maharashtra. In a major development to the top leadership change in the listed Pharma Company Dr. Datsons Labs Ltd, the announcement has come from the Meeting of the Board of Directors of the Company held on February 14, 2015. The salient features of the unaudited financial results seem to indicate a positive vibe as the sales is up 15% & net profit up from 1.97lakhs to 1.99 lakhs

Dr.Datsons Labs Ltd has informed BSE that the Board of Directors of the Company at its meeting held on February 14, 2015, inter alia, has decided to appoint Mr. Mahesh Vaidya, as the Vice Chairman and Managing Director of the Company w.e.f. February 14, 2015. Dr. Kannan Vishwanath, as the Vice Chairman and Managing Director of the Company has stepped down from the post  w.e.f. February 14, 2015. Dr.Datsons Labs Ltd had earlier appointed Mr. Sameer Talim as the  Chief Executive officer of the Company, with effect from February 09, 2015.

Sources to Pharmaleaders reveal that the appointment of Mr. Samir Talim as the CEO of Dr. Datsons Labs Ltd will be primarily to drive the company’s presence in the major markets & to aggressively build on the export orders, work on existing clients & as well as to generate new business give push to the Generic barands of Dr Datsons in Middle East, South East asia & South America. The new CEO  will also push Registrations of our formulations & enter new markets using his expertise in these markets. Mr. Samir has wide exposures in the export markets based on his successful stints in the previous assignments will help Dr. Datsons Labs penetration into the key market. India ofcourse will remain as the Key market as the company still has big companies in Contract Manufacturing.  Mr. Mahesh Vaidya  as the new Vice-Chairman & Managing Director will aggressively look into equity raising for the company. Mr. Mahesh Vaidya is entrusted with the responsibilities to meet  with the  potential investors for stake sale or fresh infusions of funds into  the company which is quite vital for the growth momentum of Dr. Datsons Labs. Ltd. There are key unfinished agenda as certain vital deals are yet to be given a finishing end including the current proposals to give new & fresh perspectives.

In an exclusive interview to Pharmaleaders ( www.pharmaleader.tv ), the new Vice-Chairman & MD, Mr Mahesh Vaidya expressed hope that the coming I year is going to be very crucial to the company’s both organic & inorganic growth as many deals, JV’s & partnership are pending for the final clearances, Dr. Datsons Labs will be closely looking at the operational efficiency of the Mahad Facility for Making APIs for Captive Use of APIs for their formulations. There are interesting & exciting times ahead of us, we all are committed to bring the company to its new height. Commenting on the state of india’s booming Pharma market, Mr Vaidya stated that India has become a prime destination for manufacture of branded, generic and branded generic medicines with a strong export element. It is estimated that around 40 per cent of the generic drugs in the US come from India and with Obamacare being introduced this figure is set to rise further. Overall market seems positive & our new CEO Mr. Sameer Talim will drive the domestic as well as the exports market, soon we will announce a breakthrough export deal that we have received from Nigeria & Yemen.

Mr. Sameer Talim stated that “Indian pharmaceutical companies have capitalised on export opportunities in regulated and semi-regulated markets and pharma exports from India grew at a CAGR in excess of 20% from 2006 to 2012. Currently, India is the third-largest exporter of Active Pharmaceutical Ingredients (APIs). Indian pharma exports are expected to bring in an estimated $40 billion by the First Quarter of 2015. With Indian products competing with their global counterparts in terms of quality, India has been able to establish a global footprint. Indian companies operating in the west have been able to do so successfully & Dr. Datsons Lab is fully equipped to meet the challenges both regulatory & operationally to cater to the world market. We are expecting a 30 % jump in exports in the second quarter which will largely be driven by the generic push”.

 Mr Sameer Talim, CEO, Dr. Datsons Labs Ltd.

Mr Sameer Talim is an B.COM & MBA from Mumbai University with entire Experience Based in  West Africa in Healthacare Marketing. He started as Management Trainee with Kinds Healthcare Limited Kampala & Rose to Become The Vice President Marketing & Operations at Sparkeway Industries in Kampala. In last 20 years he has extensive experience in West African Markets for marketing registration & Distribution of Anti Malarial Drugs, HIV & AIDS Medication. He has returned to India after 20 years due to person & domestic requirements. He has joined us & will spearhead our growth operations for Exports worldwide. Mr Sameer repeatedly produce sustained revenue and EBITA growth in dynamic and changing markets. Has proven achievements  and Extensive business background in international, multi-cultural environments. Mr. Sameer is a results-oriented Healthcare CEO with over 25 years’ experience as a Senior Executive. Strong reputation in executive leadership, strategic planning, business development, fiscal and organizational management. Demonstrated results in quality management, revenue cycle improvement and financial turnarounds. Worked in both for-profit and not-for-profit healthcare organizations and systems. Superb decision making and problem solving skills. High-energy people-person with strong communication and interpersonal skills & a  Senior executive with verifiable year-after-year success achieving revenue, profit, and business growth objectives within start-up, turnaround, and rapid-change environments. Extensive experience with highly engineered systems, which require deep understanding of critical business drivers in multiple markets and industries; highly successful in building relationships with upper-level decision makers, seizing control of critical problem areas, and delivering on customer commitments.

Mr Mahesh Vaidya

 Vice Chairman & MD, Dr. Datsons Labs Ltd.

 Mahesh Vaidya is a top Management Professional  with over 25 years of experience in the field of Finance,Accounts, Overall Business Development. This dynamic young  MD of Dr Datsons Labs, started his career with couple of Pharma Companies  through his hardwork and dedication earned the highest position in the organisation. His leadership witnessed dramatic growth and through his aggressive positioning and strategy the organisation won many laurels and awards in past. As the new VC & MD of the company, Mahesh will spearhead Dr Datsons Labs’s’s aggressive game plan to accelerate growth and take advantage of the changing business dynamics that emphasize equally, aspects of product portfolio, quality, global footprint and cost efficiency. Mahesh  has a meritorious track record, and the experience of managing large business operations earlier, with similar responsibilities.

Mr Mahesh Vaidya is BSC & MSc It from Pune University. He has over 25 years experience working in global markets . He started His  career with  Pharmed Europe Ltd  looking into their Medical devices Business. He rose to Position of Head of commercial operations in one year looking into their entire exports of Medical devices worldwide. From Pharmed Limited Europe  he Moved to Quibarkfarm Global S.A.  As Director Exports to looking into entering generic markets in South America Till January 2015. He has been appointed as the  Vice Chairman & Managing Director. Repeatedly produce sustained revenue and EBITA growth in dynamic and changing markets. Proven achievements  and Extensive business background in international, multi-cultural environments. Senior executive with verifiable year-after-year success achieving revenue, profit, and business growth objectives within start-up, turnaround, and rapid-change environments. Extensive experience with highly engineered systems, which require deep understanding of critical business drivers in multiple markets and industries; highly successful in building relationships with upper-level decision makers, seizing control of critical problem areas, and delivering on customer commitments. Mr Vaidya has shown remarkable achievements in Excellent marketing skills, exceptional ability to communicate orally and in writing, has experience of sales metric designs & demonstrated ability to work in a leadership role. A far sighted individual withover 25 years’ experience in  excellent business development skills with hands on knowledge of directing the activities of all projects. Excellent knowledge of supporting  the company’s strategic alliances and participating in marketing strategies. Hands on experience of supervising employees across different departments in order to facilitate the process of production and marketing. Mr. Vaidya has hands on experience on operations management, Acquisitions & Integrations, Organic Business Growth,Strategic Planning Staff Development-Promotion, Performance & Quality Standards,Customer Satisfaction & Allegiance Leadership Development, P&L Management/Budget Planning, Engineering & Manufacturing Change Management, Commercial & Customer Support  Strategic Partnerships. As Vice Chairman & Managing Director of Dr. Datsons Labs Ltd, Mr Mahesh Vaiday will be the driving spirit of leadership to the Board & will undertake strategic initiatives to propel the growth engine of the Company. Mr Mahesh Vaiday will have the responsibilities to identify and direct business development activities, ensure that all corporate objectives are pursued & organize activities for business development, develop strategic business plans, establish company culture, values and vision manage risk management plans.

About Dr. Datsons Lab Ltd

Dr. Datsons Lab Ltd, formerly known as Aanjaneya Lifecare Ltd, BSE code (533412) is a public listed vertically integrated company having state-of-the-art; WHO GMP approved facilities for manufacturing bulk drugs at Mahad and finished dosage forms at Pirungut near Pune. It is one of the largest contract manufacturers of codeine based cough syrups in India. The company exclusively manufactures the Codorex Brand of Zydus Cadilla and Codilite Brand of Tablets India Ltd. amongst others.The company raised about Rs. 117 crore from its IPO and the funds are being used to built new capacities along with the refurbishing of Research & Development centre. The new facilities being created as part of CAPEX are using eco friendly, recyclable material and will be rated by LEEDS once completed.The Facilities being established will comply with the latest European & US guidelines. With new capacities to be added in next 6 to 9 months the company will be expanding operations in emerging markets of South East Asia, Africa & South & Central America and its domestic operation in branded generics segment. The company with its manufacturing facilities –in Mahad, Hyderabad and Pune has to its credit many achievements. It is the world’s third-largest manufacturer of quinine salts in the world . Only nine companies globally manufacture quinine salts.One of the largest codeine based formlulations manufacturer in the pharmaceutical sector. One of the largest manufacturer of multi- flavored Lozenges in  medical products in India. The company pioneered the recognition that lozenges represent a stable platform for the delivery of pharmaceutical and nutraceutical ingredients. Dr. Datson’s Nicco Nil lozenge is a first-of-its-kind  hard boiled lozenge remedy for smoking de-addition; its Relacs is a first-time lozenge against insomnia and Arecta Plus, a lozenge variant for Erectile Dysfunction, is a first of its kind . The company has an expertise in opportunity spotting and innovation. The company’s success has been built on a business model that integrates Research, Innovation and Knowledge. The company has invested in building proprietary Knowledge through research and acquisitions. Dr. Datson’s competence has been validated through patents granted by international and Indian authorities. Production of Quinine Sulphate increased 30% in 2011-2012. Sales of Quinine Sulphate grew 45%. Exports increased 250% from Rs 10 Crore to Rs 31 crore. Added 35 international and 50 domestic clients. Completed trials for Bromexine(expectorant)a new API that will be launched in 2012-1023. Highlights 2011-2012 for Finished Dosage Forms. Launched ‘Rancorex’ an in-house codine based cough syrup brand for the first time in its history. received the Kenya PPB GMP approval from all facilities namely lozenges,liquids and ointments. Received registration for ‘Arecta Plus’(a lozenge variant of Viagra tablets)from Sierrs Leone and Libya; received the first export order for this product to be executed in 2012-2013.

Combating Cancer through wider public outreach & use of new age awareness is key – Dr. Sandeep Chatrath

Combating Cancer through wider public outreach & use of new age awareness is key  – Dr. Sandeep Chatrath

Community Outreach Strategy is Key for Cancer Prevention

The organization works to improve the health and well-being of the people and communities. Our present work focuses on strategies to make it easier for people to eat well, be tobacco- free, be physically active, and obtain preventive care.

Through these programs, our staffs works collaboratively with school districts, businesses, communities, hospitals, and healthcare provider organizations to support healthy lifestyles for our patients and community members. Specific strategies focus on policy, systems, and environmental changes that reduce risks for Cancer& chronic disease and improve quality of life for both children and adults. Hospital is committed to the surrounding community and participates in a variety of programs designed to increase awareness on Cancer.

Our community outreach programs are effective vehicles for bringing health education, screening and other health care services directly to those in need. Our efforts focus on increasing health literacy especially on prevention from cancer, providing better access to quality health care facilities and providers, and supporting communities in need by funding vital health programs.

Improving Community Health

Non-medical, non-emergent needs are often intricately tied to personal health and well-being. Hospital is working to address basic, social and personal needs as a way to improve their communities’ health. They are working not just to mend bodies, but also to make people and communities healthier. 

Various Community Outreach strategies for Cancer Prevention are :

  • Understanding mortality and morbidity due to cancer: As per WHO 33% women and 25% men are likely to get cancer in their life time. Incidence of cancer is increasing with every passing day. Battle against cancer cannot be won by doctors and scientist alone. The entire community has to be involved. It is possible to prevent 40-50 % cancers by adopting healthy life styles. By self examination, it is possible to detect 10-20 % of cancer and by annual check up for cancer, it is possible to detect 50-60 % of cancers. Cancer is curable, if detected early and treated promptly at good cancer hospitals.
  • Understanding Common cancers in India:Men: Lung, Larynx, Tongue, Mouth Oesophagus, Gall Bladder, Prostate, Non Hodgkin Lymphoma (NHL) Women: Breast, Cervix, Ovary, gall Bladder, Oesophagus, lung, Thyroid, Non Hodgkin Lymphoma (NHL), Brain
  • Understanding Warning Sign of Cancer: Change in bowel or bladder habit, Asore / wound that does not heal, Unusual bleeding or discharge from any part of the body, Thickening / lump in breast or elsewhere, Indigestion or difficulty in swallowing, Obvious change in size of a wart or mole, Nagging cough or hoarseness
  • Spreading awareness about Causes of Cancer: Tobacco and tobacco products initiate cancer, Alcohol promotes cancers, High fat foods and overweight, Infections e.g. HIV, Hepatitis B and C, Papilloma Virus etc., Genetic, Unknown.
  • Steps for Prevention of Cancer: Stop Smoking (active and passive) and alcohol to prevent lung, head and neck cancers, Avoid high fat and rich foods. Eat Whole grains, fruits and fresh vegetables to prevent cancers of breast, prostate and colon, Exercise to stay healthy, Avoid exposure to household solvent cleaners, cleaning fluids and paint thinners, pesticides, fungicides and other chemicals to avoid lung cancer. Avoid multiple sex partners to avoid cancer cervix, Avoid direct sunlight in summers to avoid skin cancers
  • Screening& Early Cancer detection :The earlier the cancer is detected / diagnosed the better are the chances of cure and complete recovery. It is important to realize that many cancers today are curable. Monthly Self Examination and Annual Cancer Screening are mandatory for early detection of cancer.
  • Monthly Self Examination:Mouth: Change in colour of gums, lips, and Cheeks, White, Brown or Red patches, Ulcer, sore or Scab, thickening in any part of the mouth. Neck: Look for any lump, Swelling or any other abnormality. Breast: Complete self breast examination for any lump, discharge from the nipple, puckering of skin. Abdomen: Any Swelling, enlargement or hardness of abdomen. Testis: Any Swelling, enlargement or hardness. Limbs: Any Swelling / Lump etc.
  • Annual Cancer Screening: Men above the age of 50 years and women above the age of 40 years must go for annual cancer screening test like the Pap Smears, mammograms, Prostate Specific Antigen (PSA) and Digital Rectal Examination (DRE) for early detection of Cancer.
  • Diagnostic and Staging Investigations for Common Cancers: Breast Cancer: FNAC / Biopsy, Mammography, Ultrasound Whole Abdomen, X-Ray Chest etc. Head & Neck Cancer: Biopsy, Direct Laryngoscope, X-Ray Chest, CT Scan (Head & Neck) etc. OesophagusCancer: Oesophagoscopy, Biopsy, EUS, CT Scan / MRI etc. Lung cancer: Bronchoscopy, Biopsy, CT Chest & Upper Abdomen, Bone Scan, MRI Brain etc. Cancer of Cervix: Pap Smear, Biopsy, LFT / RFT, Chest X-Ray, CT / MRI (Abdomen), EUA Cystoscopy / Proctoscopy. Ovarian Cancer: CA125 Blood Test, Tumour Marker, Ultrasound, Biopsy, CT Scan / MRI, Upper and Lower G.I Scopy etc. Gall Bladder Cancer: Ultrasound / EUS, Biopsy, CT Scan / MRI etc. Prostate: Digital Rectal Examination (DRE), PSA, Biopsy, Bone Scan, Pelvic CT / MRI etc.
  • How to increase chances of cancer cure: Early detection by FNAC / Biopsy, Staging work up to find out the stage of the disease, Tumour Board evaluation , Treatment of cancer at dedicated cancer centres especially NABH Accredited Cancer Hospitals, Faith in Self, God and the treating team, Positive attitude and the will to fight
  • Healthpromotion: Health awareness talk is being organized in various location of the Delhi NCR.
  • Cancer detection Camp is organized in various locations like schools, colleges, NGOs etc.

The organization pay attention and makes a plan in terms of program expectations, cost to the hospitalfor providing the programs, potential market for the programs, best use of staff currently available within the hospital, recommended and required staff for efficient and effective health promotion programs, and a potential profit margin that might allow hospitals to prospectively absorb cost and develop a feasible, effective & efficient community outreach programs.

The Author is Dr. Sandeep Chatrath , CEO, Dharamshila Hospital And Research Centre